Phase 1 Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Clinical Trials
5 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–5 of 5 trials
Recruiting
Phase 1Phase 2
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TORL Biotherapeutics, LLC155 enrolled3 locationsNCT07439653
Recruiting
Phase 1
A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
MSD R&D (China) Co., Ltd.100 enrolled15 locationsNCT06189391
Recruiting
Phase 1
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed or Refractory B-cell Non-Hodgkin Lymphoma
Autolus Limited30 enrolled8 locationsNCT06173518
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Excyte Biopharma Ltd48 enrolled1 locationNCT06565689
Recruiting
Phase 1
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
University of Utah24 enrolled1 locationNCT06824701